JP2017512801A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512801A5
JP2017512801A5 JP2016559853A JP2016559853A JP2017512801A5 JP 2017512801 A5 JP2017512801 A5 JP 2017512801A5 JP 2016559853 A JP2016559853 A JP 2016559853A JP 2016559853 A JP2016559853 A JP 2016559853A JP 2017512801 A5 JP2017512801 A5 JP 2017512801A5
Authority
JP
Japan
Prior art keywords
composition
administered
dose
body weight
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016559853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512801A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/024732 external-priority patent/WO2015157297A1/en
Publication of JP2017512801A publication Critical patent/JP2017512801A/ja
Publication of JP2017512801A5 publication Critical patent/JP2017512801A5/ja
Pending legal-status Critical Current

Links

JP2016559853A 2014-04-08 2015-04-07 Cd19抗体薬物コンジュゲートの最適な投薬 Pending JP2017512801A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461976790P 2014-04-08 2014-04-08
US61/976,790 2014-04-08
PCT/US2015/024732 WO2015157297A1 (en) 2014-04-08 2015-04-07 Optimal dosing of a cd19-antibody drug conjugate

Publications (2)

Publication Number Publication Date
JP2017512801A JP2017512801A (ja) 2017-05-25
JP2017512801A5 true JP2017512801A5 (enExample) 2018-04-26

Family

ID=54288332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016559853A Pending JP2017512801A (ja) 2014-04-08 2015-04-07 Cd19抗体薬物コンジュゲートの最適な投薬

Country Status (12)

Country Link
US (1) US20170182178A1 (enExample)
EP (1) EP3129052B1 (enExample)
JP (1) JP2017512801A (enExample)
KR (1) KR20160141727A (enExample)
CN (1) CN106170300A (enExample)
AU (1) AU2015244004A1 (enExample)
CA (1) CA2941154A1 (enExample)
EA (1) EA201692016A1 (enExample)
IL (1) IL247526A0 (enExample)
MX (1) MX2016012258A (enExample)
SG (1) SG11201607133QA (enExample)
WO (1) WO2015157297A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3481868A1 (en) * 2016-07-08 2019-05-15 Genmab A/S New dosage regimens for antibody drug conjugates based on anti-axl antibodies
KR102442736B1 (ko) * 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
CN109069584A (zh) * 2017-06-29 2018-12-21 成都华创生物技术有限公司 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法
TWI800522B (zh) 2017-12-23 2023-05-01 宇越生醫科技股份有限公司 醫藥重組受體組成物及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ583292A (en) * 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
CN101903403B (zh) * 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
SMT201700547T1 (it) * 2010-06-15 2018-01-11 Genmab As Coniugati di farmaco anticorpo umano contro il fattore tissutale
ES3004351T3 (en) * 2010-10-22 2025-03-12 Seagen Inc Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
CN106432506A (zh) * 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途

Similar Documents

Publication Publication Date Title
CY1124532T1 (el) Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JP2016530280A5 (enExample)
JP2017537905A5 (enExample)
JP2018193377A5 (enExample)
JP2017226708A5 (enExample)
JP2015007098A5 (enExample)
JP2016512513A5 (enExample)
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
RU2016109448A (ru) Комбинированная терапия для лечения глиобластомы
JP2015525798A5 (enExample)
JP2014169326A5 (enExample)
JP2016515628A5 (enExample)
JP2021505540A5 (enExample)
JP2017511793A5 (enExample)
JP2016516074A5 (enExample)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
JP2017512801A5 (enExample)
JP2017501848A5 (enExample)
JP2018530578A5 (enExample)
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
JP2018524306A5 (enExample)
JP2020524670A5 (enExample)
JP2020523384A5 (enExample)
JP2019530706A5 (enExample)